Annis Gardner Whiting Capital Advisors LLC Increases Position in DexCom, Inc. $DXCM

Annis Gardner Whiting Capital Advisors LLC grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 6,670.1% during the third quarter, HoldingsChannel reports. The firm owned 7,244 shares of the medical device company’s stock after acquiring an additional 7,137 shares during the period. Annis Gardner Whiting Capital Advisors LLC’s holdings in DexCom were worth $487,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Andra AP fonden purchased a new position in DexCom during the second quarter worth approximately $26,000. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of DexCom in the 2nd quarter worth $26,000. SJS Investment Consulting Inc. raised its holdings in shares of DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after acquiring an additional 384 shares during the period. Financial Consulate Inc. purchased a new position in shares of DexCom during the 3rd quarter worth $29,000. Finally, Sound Income Strategies LLC boosted its position in shares of DexCom by 83.8% during the 3rd quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 285 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have commented on DXCM. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $86.00 target price (up from $84.00) on shares of DexCom in a research note on Friday, January 9th. TD Cowen decreased their price objective on DexCom from $100.00 to $84.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Stifel Nicolaus assumed coverage on DexCom in a research report on Tuesday, October 21st. They issued a “buy” rating and a $85.00 price objective for the company. Piper Sandler set a $75.00 target price on DexCom and gave the company a “buy” rating in a research report on Friday, October 31st. Finally, JPMorgan Chase & Co. lowered their price target on DexCom from $90.00 to $75.00 and set a “neutral” rating for the company in a report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $86.30.

DexCom Stock Up 0.9%

Shares of DXCM opened at $74.00 on Friday. The company’s 50-day simple moving average is $67.56 and its 200-day simple moving average is $70.95. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $93.25. The stock has a market capitalization of $28.86 billion, a PE ratio of 41.11, a P/E/G ratio of 1.31 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.57 by $0.04. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The company had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter last year, the company posted $0.45 EPS. The firm’s revenue was up 21.6% compared to the same quarter last year. Analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Activity at DexCom

In related news, COO Jacob Steven Leach acquired 18,200 shares of the stock in a transaction dated Monday, November 10th. The stock was acquired at an average cost of $55.04 per share, with a total value of $1,001,728.00. Following the completion of the transaction, the chief operating officer owned 331,697 shares in the company, valued at $18,256,602.88. This represents a 5.81% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the sale, the director directly owned 27,031 shares in the company, valued at approximately $1,569,690.17. This trade represents a 3.61% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 7,866 shares of company stock worth $448,177. Company insiders own 0.32% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.